Synopse: EU-GMP-Leitfaden Kapitel 4 Documentation
|
|
|
- Rosa Baldwin
- 10 years ago
- Views:
Transcription
1 Synopse: EU-GMP-Leitfaden Kapitel 4 Documentation Am 3. Januar 2011 wurde die neue Fassung 4 Documentation durch die Europäische Kommission freigegeben. Das Kapitel wurde vollständig überarbeitet und viele Details den heutigen Anforderungen angepasst. Viele Änderungen beziehen sich auf den zunehmenden Gebrauch von elektronischer Dokumentation und Datenerfassung. Daher wurde zeitgleich auch der Annex 11 Computerised Systems überarbeitet. Das Kapitel 4 ist stark überarbeitet worden und ist nur wenig identisch mit der Vorversion. Die folgende Synopse zeigt im Detail welche Änderungen vorgenommen wurden. In der Synopse wurde versucht die entsprechenden Paragraphen gegenüberzustellen. Legende: Gelb unterlegte Paragraphen wurden überarbeitet oder neu hinzugefügt. Unterstrichene Passagen wurden ggü. der Vorversion neu hinzugefügt. Durchgestrichene Passagen in der Vorversion sind in der neuen Version nicht mehr zu finden. Version 2011 Version 2004 SANCO/C8/AM/sl/ares(2010) EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 Good Manufacturing Practice Medicinal Products for Human and Veterinary Use Chapter 4: Documentation Legal basis for publishing the detailed guidelines: Article 47 of Directive 2001/83/EC on the Community code relating to medicinal products for human use and Article 51 of Directive 2001/82/EC on the Community code relating to veterinary medicinal products. This document provides guidance for the interpretation of the principles and guidelines of good manufacturing practice (GMP) for medicinal products as laid down in Directive 2003/94/EC for medicinal products for human use and Directive 91/412/EEC for veterinary use. 2011, Deutschland, alle Rechte vorbehalten Seite 1
2 Status of the document: revision 1 Reasons for changes: the sections on "generation and control of documentation" and "retention of documents" have been revised, in the light of the increasing use of electronic documents within the GMP environment. Deadline for coming into operation: 30 June Principle Principle Good documentation constitutes an essential part of the quality assurance system and is key to operating in compliance with GMP requirements. The various types of documents and media used should be fully defined in the manufacturer's Quality Management System. Documentation may exist in a variety of forms, including paper-based, electronic or photographic media. The main objective of the system of documentation utilized must be to establish, control, monitor and record all activities which directly or indirectly impact on all aspects of the quality of medicinal products. The Quality Management System should include sufficient instructional detail to facilitate a common understanding of the requirements, in addition to providing for sufficient recording of the various processes and evaluation of any observations, so that ongoing application of the requirements may be demonstrated. There are two primary types of documentation used to manage and record GMP compliance: instructions (directions, requirements) and records/reports. Appropriate good documentation practice should be applied with respect to the type of document. Suitable controls should be implemented to ensure the accuracy, integrity, availability and legibility of documents. Instruction Good documentation constitutes an essential part of the quality assurance system. Clearly written documentation prevents errors from spoken communication and permits tracing of batch history. Specifications, Manufacturing Formulae and instructions, procedures, and records must be free from errors and available in writing. The legibility of documents is of paramount importance. 4.9 Data may be recorded by electronic data processing systems, photographic or other reliable means, but detailed procedures relating to the system in use should be available and the accuracy of the records should be checked. 2011, Deutschland, alle Rechte vorbehalten Seite 2
3 documents should be free from errors and available in writing. The term written means recorded, or documented on media from which data may be rendered in a human readable form. Required GMP documentation (by type): Site Master File: A document describing the GMP related activities of the manufacturer. Instructions (directions, or requirements) type: Specifications Describe in detail the requirements with which the products or materials used or obtained during manufacture have to conform. They serve as a basis for quality evaluation. Manufacturing Formulae, Processing, Packaging and Testing Instructions: Provide detail all the starting materials, equipment and computerised systems (if any) to be used and specify all processing, packaging, sampling and testing instructions. Inprocess controls and process analytical technologies to be employed should be specified where relevant, together with acceptance criteria. Procedures: (Otherwise known as Standard Operating Procedures, or SOPs), give directions for performing certain operations. 4.1 Specifications describe in detail the requirements with which the products or materials used or obtained during manufacture have to conform. They serve as a basis for quality evaluation. Manufacturing Formulae, Processing and Packaging Instructions state all the starting materials used and lay down all processing and packaging operations. Procedures give directions for performing certain operations e.g. cleaning, clothing, environmental control, sampling, testing, equipment operation. Protocols: Give instructions for performing and recording certain discreet operations. 2011, Deutschland, alle Rechte vorbehalten Seite 3
4 Technical Agreements: Are agreed between contract givers and acceptors for outsourced activities. Record/Report type: Records: Provide evidence of various actions taken to demonstrate compliance with instructions, e.g. activities, events, investigations, and in the case of manufactured batches a history of each batch of product, including its distribution. Records include the raw data which is used to generate other records. For electronic records regulated users should define which data are to be used as raw data. At least, all data on which quality decisions are based should be defined as raw data 4.1 Records provide a history of each batch of product, including its distribution, and also of all other relevant circumstances pertinent to the quality of the final product. Certificates of Analysis: Provide a summary of testing results on samples of products or materials(1) together with the evaluation for compliance to a stated specification. Footnote: (1) Alternatively the certification may be based, in-whole or in-part, on the assessment of real time data (summaries and exception reports) from batch related process analytical technology (PAT), parameters or metrics as per the approved marketing authorisation dossier. Reports: Document the conduct of particular exercises, projects or investigations, together with results, conclusions and recommendations. Generation and Control of Documentation 4.1 All types of document should be defined 4.9 Batch records electronically stored 2011, Deutschland, alle Rechte vorbehalten Seite 4
5 and adhered to. The requirements apply equally to all forms of document media types. Complex systems need to be understood, well documented, validated, and adequate controls should be in place. Many documents (instructions and/or records) may exist in hybrid forms, i.e. some elements as electronic and others as paper based. Relationships and control measures for master documents, official copies, data handling and records need to be stated for both hybrid and homogenous systems. Appropriate controls for electronic documents such as templates, forms, and master documents should be implemented. Appropriate controls should be in place to ensure the integrity of the record throughout the retention period. should be protected by back-up transfer on magnetic tape, microfilm, paper or other means. 4.2 Documents should be designed, prepared, reviewed, and distributed with care. They should comply with the relevant parts of Product Specification Files, Manufacturing and Marketing Authorisation dossiers, as appropriate. The reproduction of working documents from master documents should not allow any error to be introduced through the reproduction process. 4.1 Documents should be designed, prepared, reviewed and distributed with care. They should comply with the relevant parts of the manufacturing and marketing authorisation dossiers. 4.3 Documents containing instructions should be approved, signed and dated by appropriate and authorised persons. Documents should have unambiguous contents and be uniquely identifiable. The effective date should be defined. 4.3 Documents should be approved, signed and dated by appropriate and authorised persons. 4.4 Documents should have unambiguous contents; title, nature and purpose should be clearly stated. [ ] Reproduced documents should be clear and legible. The reproduction of working documents from master documents must not allow any error to be introduced through the reproduction process. 4.9 If documentation is handled by electronic data processing methods, only authorised persons should be able to enter or modify data in the computer and there should be a record of changes and deletions; access should be restricted by passwords or other means and the result of entry of critical data should be independently checked. 2011, Deutschland, alle Rechte vorbehalten Seite 5
6 4.4 Documents containing instructions should be laid out in an orderly fashion and be easy to check. The style and language of documents should fit with their intended use. Standard Operating Procedures, Work Instructions and Methods should be written in an imperative mandatory style [ ] They should be laid out in an orderly fashion and be easy to check. 4.5 Documents within the Quality Management System should be regularly reviewed and kept up-to-date. 4.5 Documents should be regularly reviewed and kept up-to-date. When a document has been revised, systems should be operated to prevent inadvertent use of superseded documents. 4.6 Documents should not be hand-written; although, where documents require the entry of data, sufficient space should be provided for such entries. 4.6 Documents should not be handwritten; although, where documents require the entry of data, [ ] Sufficient space should be provided for such entries. Good Documentation Practices 4.7 Handwritten entries should be made in clear, legible, indelible way. 4.6 [ ] these entries may be made in clear, legible, indelible handwriting. [ ] 4.8 Records should be made or completed at the time each action is taken and in such a way that all significant activities concerning the manufacture of medicinal products are traceable. 4.8 The records should be made or completed at the time each action is taken and in such a way that all significant activities concerning the manufacture of medicinal products are traceable. They should be retained for at least one year after the expiry date of the finished product. 4.9 Any alteration made to the entry on a document should be signed and dated; the alteration should permit the reading of the original information. Where appropriate, the reason for the alteration should be recorded. 4.7 Any alteration made to the entry on a document should be signed and dated; the alteration should permit the reading of the original information. Where appropriate, the reason for the alteration should be recorded. Retention of Documents 4.10 It should be clearly defined which record is related to each manufacturing activity 2011, Deutschland, alle Rechte vorbehalten Seite 6
7 and where this record is located. Secure controls must be in place to ensure the integrity of the record throughout the retention period and validated where appropriate Specific requirements apply to batch documentation which must be kept for one year after expiry of the batch to which it relates or at least five years after certification of the batch by the Qualified Person, whichever is the longer. For investigational medicinal products, the batch documentation must be kept for at least five years after the completion or formal discontinuation of the last clinical trial in which the batch was used. Other requirements for retention of documentation may be described in legislation in relation to specific types of product (e.g. Advanced Therapy Medicinal Products) and specify that longer retention periods be applied to certain documents For other types of documentation, the retention period will depend on the business activity which the documentation supports. Critical documentation, including raw data (for example relating to validation or stability), which supports information in the Marketing Authorisation should be retained whilst the authorization remains in force. It may be considered acceptable to retire certain documentation (e.g. raw data supporting validation reports or stability reports) where the data has been superseded by a full set of new data. Justification for this should be documented and should take into account the requirements for retention of batch documentation; for example, in the case of process validation data, the accompanying raw data should be retained for a period at least as long as the records for all batches whose release has been supported on the basis of that validation exercise. The following section gives some examples of required documents. The quality management system should describe all documents required to ensure product quality and patient safety. 2011, Deutschland, alle Rechte vorbehalten Seite 7
8 Specifications Specifications 4.13 There should be appropriately authorised and dated specifications for starting and packaging materials, and finished products. Specifications for starting and packaging materials 4.10 There should be appropriately authorised and dated specifications for starting and packaging materials, and finished products; where appropriate, they should be also available for intermediate or bulk products. Specifications for starting and packaging materials 4.14 Specifications for starting and primary or printed packaging materials should include or provide reference to, if applicable: a) A description of the materials, including: - The designated name and the internal code reference; - The reference, if any, to a pharmacopoeial monograph; - The approved suppliers and, if reasonable, the original producer of the material; - A specimen of printed materials; b) Directions for sampling and testing; c) Qualitative and quantitative requirements with acceptance limits; d) Storage conditions and precautions; e) The maximum period of storage before reexamination. Specifications for intermediate and bulk products 4.11 Specifications for starting and primary or printed packaging materials should include, if applicable: a) a description of the materials, including: - the designated name and the internal code reference; - the reference, if any, to a pharmacopoeial monograph; - the approved suppliers and, if possible, the original producer of the products; - a specimen of printed materials; b) directions for sampling and testing or reference to procedures; c) qualitative and quantitative requirements with acceptance limits; d) storage conditions and precautions; e) the maximum period of storage before reexamination. Specifications for intermediate and bulk products 4.15 Specifications for intermediate and bulk products should be available for critical steps or if these are purchased or dispatched. The specifications should be similar to specifica Specifications for intermediate and bulk products should be available if these are purchased or dispatched, or if data obtained from intermediate products are used for the 2011, Deutschland, alle Rechte vorbehalten Seite 8
9 tions for starting materials or for finished products, as appropriate. Specifications for finished products evaluation of the finished product. The specifications should be similar to specifications for starting materials or for finished products, as appropriate. Specifications for finished products 4.16 Specifications for finished products should include or provide reference to: a) The designated name of the product and the code reference where applicable; b) The formula; c) A description of the pharmaceutical form and package details; d) Directions for sampling and testing e) The qualitative and quantitative requirements, with the acceptance limits; f) The storage conditions and any special handling precautions, where applicable; g) The shelf-life. Manufacturing Formula and Processing Instructions 4.13 Specifications for finished products should include: a) the designated name of the product and the code reference where applicable; b) the formula or a reference to; c) a description of the pharmaceutical form and package details; d) directions for sampling and testing or a reference to procedures; e) the qualitative and quantitative requirements, with the acceptance limits; f) the storage conditions and any special handling precautions, where applicable; g) the shelf-life. Manufacturing Formula and Processing Instructions Approved, written Manufacturing Formula and Processing Instructions should exist for each product and batch size to be manufactured. Formally authorised Manufacturing Formula and Processing Instructions should exist for each product and batch size to be manufactured. They are often combined in one document The Manufacturing Formula should include: a) The name of the product, with a product reference code relating to its specification; b) A description of the pharmaceutical form, strength of the product and batch size; 4.14 The Manufacturing Formula should include: a) the name of the product, with a product reference code relating to its specification; b) a description of the pharmaceutical form, strength of the product and batch size; 2011, Deutschland, alle Rechte vorbehalten Seite 9
10 c) A list of all starting materials to be used, with the amount of each, described; mention should be made of any substance that may disappear in the course of processing; d) A statement of the expected final yield with the acceptable limits, and of relevant intermediate yields, where applicable c) a list of all starting materials to be used, with the amount of each, described using the designated name and a reference which is unique to that material; mention should be made of any substance that may disappear in the course of processing; d) a statement of the expected final yield with the acceptable limits, and of relevant intermediate yields, where applicable The Processing Instructions should include: a) A statement of the processing location and the principal equipment to be used; b) The methods, or reference to the methods, to be used for preparing the critical equipment (e.g. cleaning, assembling, calibrating, sterilising); c) Checks that the equipment and work station are clear of previous products, documents or materials not required for the planned process, and that equipment is clean and suitable for use; d) Detailed stepwise processing instructions [e.g. checks on materials, pre-treatments, sequence for adding materials, critical process parameters (time, temp etc)]; e) The instructions for any in-process controls with their limits; f) Where necessary, the requirements for bulk storage of the products; including the container, labeling and special storage conditions where applicable; 4.15 The Processing Instructions should include: a) a statement of the processing location and the principal equipment to be used; b) the methods, or reference to the methods, to be used for preparing the critical equipment (e.g. cleaning, assembling, calibrating, sterilising); c) detailed stepwise processing instructions (e.g. checks on materials, pre-treatments, sequence for adding materials, mixing times, temperatures); d) the instructions for any in-process controls with their limits; e) where necessary, the requirements for bulk storage of the products; including the container, labelling and special storage conditions where applicable; f) any special precautions to be observed. g) Any special precautions to be observed. Packaging Instructions Packaging Instructions 4.19 Approved Packaging Instructions for each product, pack size and type should exist There should be formally authorised Packaging Instructions for each product, pack size and type. 2011, Deutschland, alle Rechte vorbehalten Seite 10
11 These should include, or have a reference to, the following: a) Name of the product; including the batch number of bulk and finished product b) Description of its pharmaceutical form, and strength where applicable; c) The pack size expressed in terms of the number, weight or volume of the product in the final container; d) A complete list of all the packaging materials required, including quantities, sizes and types, with the code or reference number relating to the specifications of each packaging material; e) Where appropriate, an example or reproduction of the relevant printed packaging materials, and specimens indicating where to apply batch number references, and shelf life of the product; f) Checks that the equipment and work station are clear of previous products, documents or materials not required for the planned packaging operations (line clearance), and that equipment is clean and suitable for use. g) Special precautions to be observed, including a careful examination of the area and equipment in order to ascertain the line clearance before operations begin; These should normally include, or have a reference to, the following: a) name of the product; b) description of its pharmaceutical form, and strength where applicable; c) the pack size expressed in terms of the number, weight or volume of the product in the final container; d) a complete list of all the packaging materials required for a standard batch size, including quantities, sizes and types, with the code or reference number relating to the specifications of each packaging material; e) where appropriate, an example or reproduction of the relevant printed packaging materials, and specimens indicating where to apply batch number references, and shelf life of the product; f) special precautions to be observed, including a careful examination of the area and equipment in order to ascertain the line clearance before operations begin; g) a description of the packaging operation, including any significant subsidiary operations, and equipment to be used; h) details of in-process controls with instructions for sampling and acceptance limits. h) A description of the packaging operation, including any significant subsidiary operations, and equipment to be used; i) Details of in-process controls with instructions for sampling and acceptance limits. Batch Processing Record Batch Processing Records 4.20 A Batch Processing Record should be kept for each batch processed. It should be based on the relevant parts of the currently 4.17 A Batch Processing Record should be kept for each batch processed. It should be based on the relevant parts of the currently 2011, Deutschland, alle Rechte vorbehalten Seite 11
12 approved Manufacturing Formula and Processing Instructions, and should contain the following information: a) The name and batch number of the product; b) Dates and times of commencement, of significant intermediate stages and of completion of production; c) Identification (initials) of the operator(s) who performed each significant step of the process and, where appropriate, the name of any person who checked these operations; d) The batch number and/or analytical control number as well as the quantities of each starting material actually weighed (including the batch number and amount of any recovered or reprocessed material added); e) Any relevant processing operation or event and major equipment used; f) A record of the in-process controls and the initials of the person(s) carrying them out, and the results obtained; g) The product yield obtained at different and pertinent stages of manufacture; h) Notes on special problems including details, with signed authorisation for any deviation from the Manufacturing Formula and Processing Instructions; i) Approval by the person responsible for the processing operations. Note: Where a validated process is continuously monitored and controlled, then automatically generated reports may be limited to compliance summaries and exception/ outofspecification (OOS) data reports. approved Manufacturing Formula and Processing Instructions. The method of preparation of such records should be designed to avoid transcription errors. The record should carry the number of the batch being manufactured. Before any processing begins, there should be recorded checks that the equipment and work station are clear of previous products, documents or materials not required for the planned process, and that equipment is clean and suitable for use. During processing, the following information should be recorded at the time each action is taken and, after completion, the record should be dated and signed in agreement by the person responsible for the processing operations: a) the name of the product; b) dates and times of commencement, of significant intermediate stages and of completion of production; c) name of the person responsible for each stage of production; d) initials of the operator of different significant steps of production and, where appropriate, of the person who checked each of these operations (e.g. weighing); e) the batch number and/or analytical control number as well as the quantities of each starting material actually weighed (including the batch number and amount of any recovered or reprocessed material added); f) any relevant processing operation or event and major equipment used; g) a record of the in-process controls and the initials of the person(s) carrying them out, and the results obtained; h) the product yield obtained at different and pertinent stages of manufacture; 2011, Deutschland, alle Rechte vorbehalten Seite 12
13 i) notes on special problems including details, with signed authorisation for any deviation from the Manufacturing Formula and Processing Instructions. Batch Packaging Record Batch Packaging Records 4.21 A Batch Packaging Record should be kept for each batch or part batch processed. It should be based on the relevant parts of the Packaging Instructions. The batch packaging record should contain the following information: a) The name and batch number of the product, b) The date(s) and times of the packaging operations; c) Identification (initials) of the operator(s) who performed each significant step of the process and, where appropriate, the name of any person who checked these operations; d) Records of checks for identity and conformity with the packaging instructions, including the results of in-process controls; e) Details of the packaging operations carried out, including references to equipment and the packaging lines used; f) Whenever possible, samples of printed packaging materials used, including specimens of the batch coding, expiry dating and any additional overprinting; g) Notes on any special problems or unusual events including details, with signed authorisation for any deviation from the Packaging Instructions; h) The quantities and reference number or identification of all printed packaging materials and bulk product issued, used, destroyed or returned to stock and the quantities of obtained product, in order to provide for an 4.18 A Batch Packaging Record should be kept for each batch or part batch processed. It should be based on the relevant parts of the Packaging Instructions and the method of preparation of such records should be designed to avoid transcription errors. The record should carry the batch number and the quantity of bulk product to be packed, as well as the batch number and the planned quantity of finished product that will be obtained. Before any packaging operation begins, there should be recorded checks that the equipment and work station are clear of previous products, documents or materials not required for the planned packaging operations, and that equipment is clean and suitable for use. The following information should be entered at the time each action is taken and, after completion, the record should be dated and signed in agreement by the person(s) responsible for the packaging operations: a) the name of the product; b) the date(s) and times of the packaging operations; c) the name of the responsible person carrying out the packaging operation; d) the initials of the operators of the different significant steps; e) records of checks for identity and conformity with the packaging instructions including the results of in-process controls; f) details of the packaging operations carried 2011, Deutschland, alle Rechte vorbehalten Seite 13
14 adequate reconciliation. Where there are there are robust electronic controls in place during packaging there may be justification for not including this information i) Approval by the person responsible for the packaging operations out, including references to equipment and the packaging lines used; g) whenever possible, samples of printed packaging materials used, including specimens of the batch coding, expiry dating and any additional overprinting; h) notes on any special problems or unusual events including details, with signed authorisation for any deviation from the Manufacturing Formula and Processing Instructions; i) the quantities and reference number or identification of all printed packaging materials and bulk product issued, used, destroyed or returned to stock and the quantities of obtained product, in order to provide for an adequate reconciliation. Procedures and records Procedures and records Receipt Receipt 4.22 There should be written procedures and records for the receipt of each delivery of each starting material, (including bulk, intermediate or finished goods), primary, secondary and printed packaging materials There should be written procedures and records for the receipt of each delivery of each starting and primary and printed packaging material The records of the receipts should include: a) The name of the material on the delivery note and the containers; b) The "in-house" name and/or code of material (if different from a); c) Date of receipt; d) Supplier s name and, manufacturer s name; e) Manufacturer s batch or reference number; f) Total quantity and number of containers 4.20 The records of the receipts should include: a) the name of the material on the delivery note and the containers; b) the "in-house" name and/or code of material (if different from a); c) date of receipt; d) supplier s name and, if possible, manufacturer s name; e) manufacturer s batch or reference number; f) total quantity, and number of containers 2011, Deutschland, alle Rechte vorbehalten Seite 14
15 received; g) The batch number assigned after receipt; h) Any relevant comment. received; g) the batch number assigned after receipt; h) any relevant comment (e.g. state of the containers) There should be written procedures for the internal labeling, quarantine and storage of starting materials, packaging materials and other materials, as appropriate. Sampling 4.21 There should be written procedures for the internal labelling, quarantine and storage of starting materials, packaging materials and other materials, as appropriate. Sampling 4.25 There should be written procedures for sampling, which include the methods and equipment to be used, the amounts to be taken and any precautions to be observed to avoid contamination of the material or any deterioration in its quality. Testing 4.22 There should be written procedures for sampling, which include the person(s) authorised to take samples, the methods and equipment to be used, the amounts to be taken and any precautions to be observed to avoid contamination of the material or any deterioration in its quality (see Chapter 6, item 13). Testing 4.26 There should be written procedures for testing materials and products at different stages of manufacture, describing the methods and equipment to be used. The tests performed should be recorded. Other 4.23 There should be written procedures for testing materials and products at different stages of manufacture, describing the methods and equipment to be used. The tests performed should be recorded (see Chapter 6, item 17). Other 4.27 Written release and rejection procedures should be available for materials and products, and in particular for the certification for sale of the finished product by the Qualified Person(s). All records should be available to the Qualified Person. A system should be in place to indicate special observations and any changes to critical data Written release and rejection procedures should be available for materials and products, and in particular for the release for sale of the finished product by the Qualified Person(s) in accordance with the requirements of Article 51 of Directive 2001/83/EC (Article 55 of Directive 2001/82/EC) Records should be maintained for the 4.25 Records should be maintained of the 2011, Deutschland, alle Rechte vorbehalten Seite 15
16 distribution of each batch of a product in order to facilitate recall of any batch, if necessary. distribution of each batch of a product in order to facilitate the recall of the batch if necessary (see Chapter 8) There should be written policies, procedures, protocols, reports and the associated records of actions taken or conclusions reached, where appropriate, for the following examples: - Validation and qualification of processes, equipment and systems; - Equipment assembly and calibration; - Technology transfer; - Maintenance, cleaning and sanitation; - Personnel matters including signature lists, training in GMP and technical matters, clothing and hygiene and verification of the effectiveness of training. - Environmental monitoring; - Pest control; 4.26 There should be written procedures and the associated records of actions taken or conclusions reached, where appropriate, for: - validation; - equipment assembly and calibration; - maintenance, cleaning and sanitation; - personnel matters including training, clothing, hygiene; - environmental monitoring; - pest control; - complaints; - recalls; - returns. - Complaints; - Recalls; - Returns; - Change control; - Investigations into deviations and nonconformances; - Internal quality/gmp compliance audits; - Summaries of records where appropriate (e.g. product quality review); - Supplier audits Clear operating procedures should be available for major items of manufacturing and test equipment Clear operating procedures should be available for major items of manufacturing and test equipment. 2011, Deutschland, alle Rechte vorbehalten Seite 16
17 4.31 Logbooks should be kept for major or critical analytical testing, production equipment, and areas where product has been processed. They should be used to record in chronological order, as appropriate, any use of the area, equipment/method, calibrations, maintenance, cleaning or repair operations, including the dates and identity of people who carried these operations out Log books should be kept for major or critical equipment recording, as appropriate, any validations, calibrations, maintenance, cleaning or repair operations, including the dates and identity of people who carried these operations out Log books should also record in chronological order the use of major or critical equipment and the areas where the products have been processed An inventory of documents within the Quality Management System should be maintained. CHAPTER 4 DOCUMENTATION Die Synopse wurde erstellt durch: Maas & Peither AG, GMP-Verlag Karlstrasse 2, Schopfheim, Deutschland 13. Januar 2010 EU-GMP-Leitfaden Ringordner + CD-ROM - EU-Richtlinien - EU-GMP-Leitfaden Teil I für Arzneimittel - EU-GMP-Leitfaden Teil II für Wirkstoffe - Anhänge 1-20 Preis 98,- zzgl. MwSt. Seiten 650 ISBN Weitere Infos unter , Deutschland, alle Rechte vorbehalten Seite 17
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Pharmaceuticals Brussels, SANCO/C8/AM/sl/ares(2010)1064587 EudraLex The Rules Governing Medicinal Products
Synopse: EU-GMP- Leitfaden Annex 11 Computerised Systems
Synopse: EU-GMP- Leitfaden Annex 11 Computerised Systems Am 3. Januar 2011 wurde die neue Fassung des Annex 11 Computerised Systems durch die Europäische Kommission freigegeben. Der Annex wurde überarbeitet,
Guide to Master Formulae WHO/FWC/IVB/QSS/VQR
WHO/FWC/IVB/QSS/VQR 2011 This guidance document GUIDE TO MASTER FORMULAE is one of a series developed by WHO/FWC/IVB Quality, Safety & Standards team upon request from the manufacturers members of the
COMMISSION DIRECTIVE 2003/94/EC
L 262/22 COMMISSION DIRECTIVE 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Pharmaceuticals Brussels, SANCO/C8/AM/sl/ares(2010)1064599 EudraLex The Rules Governing Medicinal Products
GMP-Z Hoofdstuk 4 Documentatie. Inleiding
-Z Hoofdstuk 4 Documentatie Inleiding Het hoofdstuk Documentatie uit de -richtsnoeren is in zijn algemeenheid goed toepasbaar in de ziekenhuisapotheek. Verschil met de industriële is dat de bereidingen
Version 1.0 November 2013 Developed by: Working group of the HPAI Aseptic Services Special Interest Group (ASSIG)
(H-PIC\S) Version 1.0 November 2013 Developed by: Working group of the HPAI Aseptic Services Special Interest Group (ASSIG) The working group of the HPAI ASSIG was chaired by: Aisling Collins BSc (Pharm),
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products- authorisations, European Medicines Agency Brussels, EudraLex The Rules Governing Medicinal
Vergleich der Versionen von Kapitel 1 des EU-GMP-Leitfaden (Oktober 2012) 01 July 2008 18 November 2009 31 Januar 2013 Kommentar Maas & Peither
Chapter 1 Quality Management Chapter 1 Quality Management System Chapter 1 Pharmaceutical Quality System Principle The holder of a Manufacturing Authorisation must manufacture medicinal products so as
Example of a food company quality
Appendix A manual Example of a food company quality Contents Date: 13/03/95 RME-QLMN-OO Page 1 of 3 Section Title ISO 9001 reference 01 In trod uction 02 Purpose 03 Scope 04 Definitions 05 Management responsibility
Vergleich der Versionen von Kapitel 7 des EU-GMP-Leitfadens (September 2012)
(Valid until January 31, Principle Contract manufacture and analysis must be correctly defined, agreed and controlled in order to avoid misunderstandings which could result in a product or work of unsatisfactory
Pharmaceutical Wholesaler Site Inspection Checklist
Pharmaceutical Wholesaler Site Inspection Checklist Date and time of inspection: Legal business name and plant name: Location (address): Phone number: Fax number: Email address: Web site URL: Contact Person:
JANUARY 2013 PREPARATION OF A SITE MASTER FILE FOR A MANUFACTURER OF COSMETIC PRODUCTS
JANUARY 2013 PREPARATION OF A SITE MASTER FILE FOR A MANUFACTURER OF COSMETIC PRODUCTS 1 WHAT IS A SITE MASTER FILE? A Site Master File (SMF) is a document prepared by the manufacturer containing specific
Annex 9 Guide to good storage practices for pharmaceuticals 1
World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 9 Guide to good storage practices for pharmaceuticals 1 1. Introduction 125 2. Glossary 126 3. Personnel 128 4. Premises and facilities
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union.
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 03 February 2010 ENTR/F/2/AM/an D(2010) 3374 EudraLex The Rules Governing Medicinal Products in
Annex 2. WHO good manufacturing practices for pharmaceutical products: main principles 1
Annex 2 WHO good manufacturing practices for pharmaceutical products: main principles 1 Introduction 79 General considerations 80 Glossary 81 Quality management in the medicines industry: philosophy and
SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT
SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoption
MHRA GMP Data Integrity Definitions and Guidance for Industry March 2015
MHRA GMP Data Integrity Definitions and Guidance for Industry Introduction: Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality. This
Quality Management System for Active pharmaceutical Ingredients manufacturers. Integrating GMP into ISO 9001
Quality Management System for Active pharmaceutical Ingredients manufacturers Integrating GMP into ISO 900 December 997 Table of contents A. Acknowledgement... 3 B. Introduction... 5 C. Glossary... 8 D.
Annex 2 Good trade and distribution practices for pharmaceutical starting materials
World Health Organization WHO Technical Report Series, No. 917, 2003 Annex 2 ood trade and distribution practices for pharmaceutical starting materials Introductory note 36 Scope 37 eneral considerations
MHRA GMP Data Integrity Definitions and Guidance for Industry January 2015
MHRA GMP Data Integrity Definitions and Guidance for Industry Introduction: Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality. This
New Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 68/01)
Safeguarding public health New Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 68/01) Tony Orme, Senior GDP Inspector Inspection, Enforcement and Standards Division
PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013)
January 2013 RESTRICTED PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) DRAFT FOR COMMENTS Please address any comments on this proposal
Company Quality Manual Document No. QM Rev 0. 0 John Rickey Initial Release. Controlled Copy Stamp. authorized signature
Far West Technology, Inc. ISO 9001 Quality Manual Document No.: QM Revision: 0 Issue Date: 27 August 1997 Approval Signatures President/CEO Executive Vice President Vice President/CFO Change Record Rev
MeriCal Quality Profile
January 5, 2015 Dear Valued Customer, Since the implementation of new federal regulations, MeriCal Inc. has received a large volume of questionnaires and surveys regarding our services and procedures.
Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice
Version 8 (final) EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 S\common\legal-legislation\75-319nd81-851\91-356\eudralexvol4\Annex
Community Guide to Good Practice For Feed Additive and Premixture Operators
Community Guide to Good Practice For Feed Additive and Premixture Operators INTRODUCTION This European Guide of Practice for Animal Feed Additive and Premixture Operators ( Guide ) responds to the Regulation
[SCHEDULE M] [See Rules 71, 74, 76 and 78] GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS.
[SCHEDULE M] [See Rules 71, 74, 76 and 78] GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS. Note: - To achieve the objectives listed below, each
This interpretation of the revised Annex
Reprinted from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE July/August 2011, Vol. 31 No. 4 www.ispe.org Copyright ISPE 2011 The ISPE GAMP Community of Practice (COP) provides its interpretation
Audit Report in the framework of the APIC Audit Programme
Audit Report in the framework of the APIC Audit Programme Company Location Address Country Subject of Audit Audit Date Auditor (lead) Co-Auditor(s) Participants Signature of Auditor(s) Lead Auditor Co-Auditor
NSF Dietary Supplement
NSF Dietary Supplement SOP Template Book A guide to achieving and maintaining compliance to 21 CFR 111: Dietary Supplement Good Manufacturing Practices 2 Contents How to Use...4 About NSF Dietary Supplements...5
GMP Issues for Start-Ups, quality in the supply chain and role of the Qualified Person (QP)
GMP Issues for Start-Ups, quality in the supply chain and role of the Qualified Person (QP) Presented by: Patrick Costello Scientific Administrator, European Medicines Agency An agency of the European
Quality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:
NOTE TO USERS This Quality Agreement template was developed by the Bulk Pharmaceutical Task Force (BPTF), an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA), as a
Quality Information. Buchs Manufacturing Site
Buchs Manufacturing Site Related Documents Buchs ISO 9001:2008 Certificate Buchs cgmp Certificate Buchs ISO 13485:2012 Certificate Buchs ISO 17025:2005/ ISO Guide 34 Certificate Buchs Management System
EudraLex. The Rules Governing Medicinal Products in the European Union Volume 4
Ref. Ares(2015)283695-23/01/2015 PT CHAPTER 5 PRODUCTION EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy EudraLex
SCHEDULE M GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS
SCHEDULE M GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS GAZETTE OF INDIA EXTRAORDINARY, PART II-SECTION 3, SUB-SECTION (i)] MINISTRY OF HEALTH
Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015
Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015 *QP Code of Practice 2008 updated Aug15 Page 1 of 13 Code of Practice for Qualified Persons 1. INTRODUCTION 2.
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Pharmaceuticals Brussels, SANCO/C8/AM/an D(2010) 380358 EudraLex The Rules Governing Medicinal Products in
Generic CMMS Quality Assurance Plan
Generic CMMS Quality Assurance Plan Scope In accordance with the Quality Policy, the Quality System of CMMS is based upon the requirements and structure of ISO (the International Organization for Standardization)
Food Safety and Quality Management System
Introduction The company has planned, established, documented and implemented a food safety and quality management system for the site, which is maintained in order to continually improve its effectiveness
GOOD DISTRIBUTION PRACTICE FOR MEDICAL DEVICES (GDPMD)
MEDICAL DEVICE CONTROL DIVISION Ministry of Health, Malaysia Regulatory Requirements for Medical Device Safety & Performance GOOD DISTRIBUTION PRACTICE FOR MEDICAL DEVICES (GDPMD) DRAFT DRAFT 1 September
GCP INSPECTORS WORKING GROUP <DRAFT> REFLECTION PAPER ON EXPECTATIONS FOR ELECTRONIC SOURCE DOCUMENTS USED IN CLINICAL TRIALS
European Medicines Agency London, 17 October 2007 Doc. Ref. EMEA/505620/2007 GCP INSPECTORS WORKING GROUP REFLECTION PAPER ON EXPECTATIONS FOR ELECTRONIC SOURCE DOCUMENTS USED IN CLINICAL TRIALS
Welcome Computer System Validation Training Delivered to FDA. ISPE Boston Area Chapter February 20, 2014
Welcome Computer System Validation Training Delivered to FDA ISPE Boston Area Chapter February 20, 2014 1 Background Training Conducted on April 24, 2012 Food & Drug Administration Division of Manufacturing
OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT
OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT PA/PH/OMCL (08) 69 3R Full document title and reference Document type VALIDATION OF COMPUTERISED SYSTEMS Legislative basis - CORE DOCUMENT
Annex 4 Good Manufacturing Practices for pharmaceutical products: main principles
World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 4 Good Manufacturing Practices for pharmaceutical products: main principles Introduction 37 General considerations 39 Glossary
How To Inspect A Blood Bank
Site visit inspection report on compliance with HTA minimum standards Belfast Cord Blood Bank HTA licensing number 11077 Licensed for the procurement, processing, testing, storage, distribution and import/export
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
Ref. Ares(2013)148102-05/02/2013 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, SANCO/D/6/SF/mg/ddg1.d.6(2013)179367
Good Research Practice
Page 1 of 8 The Royal Veterinary College Introduction Preface Good Research Practice Funding bodies need to be assured of the quality and validity of research they fund and ensure their contractors are
Standard Operating Procedure Title: Manufacturing Rework Procedure
DR BPN RBPN WIP Deviation Report Batch Production Number Reworked Batch Production Number Work in Progress Area PS1 Production Staging Area 1 PS2 Production Staging Area 2 IP Interim Production Staging
MEDICAL DEVICE GUIDANCE
May 2014 MEDICAL DEVICE GUIDANCE GN-23: Guidance on Labelling for Medical Devices PREFACE This document is intended to provide general guidance. Although we have tried to ensure that the information contained
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL
Schweppes Australia Head Office Level 5, 111 Cecil Street South Melbourne Victoria 3205. www.schweppesaustralia.com.au
Schweppes Australia Head Office Level 5, 111 Cecil Street South Melbourne Victoria 3205 www.schweppesaustralia.com.au Quality Management Systems 1. Quality Management Systems develop, implement, verify
Annex 5 WHO good distribution practices for pharmaceutical products
World Health Organization WHO Technical Report Series, No. 957, 2010 Annex 5 WHO good distribution practices for pharmaceutical products 1. Introduction 2. Scope of the document 3. Glossary 4. General
ASTRAZENECA GLOBAL POLICY QUALITY AND REGULATORY COMPLIANCE
ASTRAZENECA GLOBAL POLICY QUALITY AND REGULATORY COMPLIANCE THIS POLICY OUTLINES THE TOP LEVEL REQUIREMENTS TO SUPPORT PRODUCT QUALITY IN THE DEVELOPMENT, MANUFACTURE AND DISTRIBUTION OF ACTIVE PHARMACEUTICAL
MEDFORD FABRICATION CSC, INC. Quality System Manual. Date of issue: 03/25/2010 Revision : F
MEDFORD FABRICATION CSC, INC Quality System Manual Date of issue: 03/25/2010 Revision : F Table of Contents System Description 1.0 Introduction 2.0 Company Quality Policy 3.0 Organization Charts 4.0 Quality
Adoption by GCP Inspectors Working Group for consultation 14 June 2011. End of consultation (deadline for comments) 15 February 2012
10 December 2013 EMA/INS/GCP/600788/2011 Compliance and Inspection Reflection paper on the use of interactive response technologies (interactive voice/web response systems) in clinical trials, with particular
Guide to Quality System for General Sale Wholesale Distributors
Guide to Quality System for General Sale Wholesale Distributors IA-G0038-2 1 NOVEMBER 2013 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.
Quality Management System Manual
Quality Management System Manual Assurance ISO / AS Manual Quality Management System EXCEEDING ALL EXPECTATIONS Since our inception in 1965, Swiss-Tech has supplied the medical, aerospace, hydraulic, electronic
Guide to Distribution of Cosmetic Products in Ireland
Guide to Distribution of Cosmetic Products in Ireland ADV-G0012-2 17 JUNE 2013 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS
RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING
RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING July 2006 TABLE OF CONTENTS Page 1. Introduction 2 2. Scope 2 3. Documents to be archived 2 4. Quality of essential documents 10 5.
Questionnaire Layout:
Raw Material Supplier Questionnaire Introduction: This questionnaire has been developed by the EHPM quality working group. It combines work carried out by EHPM various national associations in developing
Data Governance Planning PDA 12 May 2015
Data Governance Planning PDA 12 May 2015 1 Agenda Overview of Data Integrity Assurance of Data Data Governance The Data Governance Plan Questions 2 Overview of Data Integrity 3 Data Information derived
DEC STD 017-2 - ISO 9002 - Quality Systems - Model for Quality Assurance in Production and Installation
Digital Internal Use Only DEC STD 017-2 - ISO 9002 - Quality Systems - Model for Quality Assurance in Production and Installation DOCUMENT IDENTIFIER: A-DS-EL00017-02-0000 Rev A, ABSTRACT: This standard
Annex 1 WHO good practices for pharmaceutical quality control laboratories
World Health Organization WHO Technical Report Series, No. 957, 2010 Annex 1 WHO good practices for pharmaceutical quality control laboratories General considerations Glossary Part one. Management and
COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS
COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS Primer CONTENTS INTRODUCTION...3 QUALITY AND COMPLIANCE IN QUALITY CONTROL LABORATORIES...5 Compliance
SUPPLIER QUALITY MANAGEMENT SYSTEM QUESTIONNAIRE
Company Name Street Address City, State, Zip code Phone Number Fax Company Website Email Address ORGANIZATION NAME PHONE NUMBER EMAIL ADDRESS President/CEO General Manager Engineering Manager Production
21 CFR Part 11 White Paper
21 CFR Part 11 White Paper Version V8.00 SR1 ProLeiT AG Einsteinstrasse 8, D-91074 Herzogenaurach, Germany Phone: +49 (0) 9132 777-0 Fax: +49 (0) 9132 777-150 E-Mail: [email protected] Internet: http://www.proleit.com
SQF Level 2 Proposed Preventive Controls Comparison Modules 2 & 11
http://leavittpartners.com/global-food-solutions Contact: [email protected] April 2013 SQF Level 2 Proposed Preventive Controls Comparison Modules 2 & 11 Introduction SQF Level 2, which
GMP Training Course Quality Control. 20-21 October 2009. Lesley Graham Senior Inspector (UK)
GMP Training Course Quality Control 20-21 October 2009 Lesley Graham Senior Inspector (UK) Quality Control GMP in the QC Laboratory Certificates of Analysis Dealing with out of specification results Parametric
GUIDELINES FOR IMPLEMTING GMP IN FOOD PROCESSING
GUIDELINES FOR IMPLEMTING GMP IN FOOD PROCESSING 2.Storage Facilities 2.1 Use of off site facilities - are they controlled 2.1.1 Where the manufacturer commissions the services of (or contracts to) off
Quality Manual PA3-01-001
Rev 01C February 2008 2008, PhaseLink Corporation PhaseLink is the trademark of PhaseLink Corporation, www.phaselink.com CONTENTS 1. Purpose and scope:...3 1.1. Purpose:...3 1.2. Scope:...3 2. Introduction
GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL INGREDIENTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE DRAFT CONSENSUS GUIDELINE GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL
Good Clinical Laboratory Practice (GCLP) An international quality system for laboratories which undertake the analysis of samples from clinical trials
Good Clinical Laboratory Practice (GCLP) An international quality system for laboratories which undertake the analysis of samples from clinical trials Vanessa Grant and Tim Stiles VERSION 2 Published by
Auditing as a Component of a Pharmaceutical Quality System
Auditing as a Component of a Pharmaceutical Quality System Tim Fields Conducting internal audits (or self inspections) and external audits of suppliers and outsourcing operations are key elements of a
GOOD DOCUMENTATION AND QUALITY MANAGEMENT PRINCIPLES. Vimal Sachdeva Technical Officer (Inspector), WHO Prequalification of Medicines Programme
GOOD DOCUMENTATION AND QUALITY MANAGEMENT PRINCIPLES Vimal Sachdeva Technical Officer (Inspector), WHO Prequalification of Medicines Programme Contents 1. Why good documentation is essential? 2. What constitutes
Quality Agreement Template
Quality Agreement Template Prepared by Dan O Leary Ombu Enterprises, LLC 3 Forest Ave. Swanzey, NH 03446 603-209-0600 This document is intended to form the basis for a Supplier Agreement. The document
Specialties Manufacturing. Talladega Castings & Machine Co., Inc. ISO 9001:2008. Quality Manual
Specialties Manufacturing Talladega Castings & Machine Co., Inc. ISO 9001:2008 This document is the property of TMS and may not be reproduced, wholly, or in part, without the express consent of TMS. Rev.
Recent Updates on European Requirements and what QPs are expected to do
Recent Updates on European Requirements and what QPs are expected to do QP Forum 28/29 November 2013, Lisbon Dr. Bernd Renger Modified: Georg Goestl 1 Written Conformation for API-Import Actual Status
Table of Contents 1. SCOPE... 3 2. APPLICABLE DOCUMENTS... 4 3. TERMS AND DEFINITIONS... 4 4. QUALITY MANAGEMENT SYSTEM...4-8
Table of Contents 1. SCOPE... 3 2. APPLICABLE DOCUMENTS... 4 3. TERMS AND DEFINITIONS... 4 4. QUALITY MANAGEMENT SYSTEM...4-8 5. MANAGEMENT RESPONSIBILITY...8-9 6. RESOURCE MANAGEMENT... 10 7. PRODUCT
ICH guideline Q10 on pharmaceutical quality system
September 2015 EMA/CHMP/ICH/214732/2007 Committee for Human Medicinal Products Step 5 Transmission to CHMP May 2007 Transmission to interested parties May 2007 Deadline for comments November 2007 Final
Quality Manual # QS001.3. MD Logistics, Inc. (Signed copy available upon request) Prepared by Robert Grange, Director Quality
# QS001.3 MD Logistics, Inc. (Signed copy available upon request) Prepared by Robert Grange, Director Quality Date Review indicates that qualified persons from operational areas have reviewed the content
Standard Practice for Quality Control Systems for Nondestructive Testing Agencies 1
Designation: E 1212 99 AMERICAN SOCIETY FOR TESTING AND MATERIALS 100 Barr Harbor Dr., West Conshohocken, PA 19428 Reprinted from the Annual Book of ASTM Standards. Copyright ASTM Standard Practice for
International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation
International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation Ludwig Huber, Ph.D. [email protected] Overview GMP requirements for Quality Control laboratories
Good Manufacturing Practices for the Production of Packaging Inks formulated for use on the non food contact surfaces of food packaging and articles
Good Manufacturing Practices for the Production of Packaging Inks formulated for use on the non food contact surfaces of food packaging and articles intended to come into contact with food October 2005
Guide to Good Distribution Practice of Medicinal Products for Human Use
Guide to Good Distribution Practice of Medicinal Products for Human Use IA-G0046-2 10 APRIL 2014 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes
Good Manufacturing Practices (GMP) for Pharmaceutical Excipients
Not for publication. This draft text is for circulation for approval by the Joint Committee and has not been published or otherwise officially promulgated. All rights reserved. This document may be reproduced
GOOD MANUFACTURING PRACTICES GUIDANCE DOCUMENT
GOOD MANUFACTURING PRACTICES GUIDANCE DOCUMENT Natural Health Products Directorate August 2006 Version 2.0 Our mission is to help the people of Canada maintain and improve their health, while respecting
PHARMACEUTICAL QUALITY SYSTEM Q10
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL QUALITY SYSTEM Q10 Current Step
Quality Assurance. Disclosure for Lilli Møller Andersen. No relevant financial relationships exist for any issue mentioned in this presentation
Quality Assurance Disclosure for Lilli Møller Andersen No relevant financial relationships exist for any issue mentioned in this presentation Agenda Quality Assurance Quality Management System Quality
Cartel Electronics. AS 9100 Quality Systems Manual
Cartel Electronics AS 9100 Quality Systems Manual 1900 C Petra Lane Placentia, California 92870 Introduction Cartel Electronics, as a global supplier to the aviation, space, and space industries, has developed
Quality Management System Policy Manual
Quality Management System Burns Engineering, Inc. 10201 Bren Road East Minnetonka, MN 55343 4. 4.1 General Requirements The Quality Manual consists of the quality system policy documents and the quality
Product Liability Risk Control Checklist
Product Liability Risk Control Checklist Appendix C1 This material will help you evaluate your products liability exposure. It is designed to enable you to focus on areas that need to be addressed to safeguard
GLUTEN-FREE CERTIFICATION PROGRAM
Self Evaluation Checklist Use this checklist to internally review your facility policy and procedures to determine how they compare with the requirements needed to successfully pass the Gluten-Free Certification
ISO/IEC 17025 QUALITY MANUAL
1800 NW 169 th Pl, Beaverton, OR 97006 Revision F Date: 9/18/06 PAGE 1 OF 18 TABLE OF CONTENTS Quality Manual Section Applicable ISO/IEC 17025:2005 clause(s) Page Quality Policy 4.2.2 3 Introduction 4
Self-Audit Checklist
Page 1 Company Name: Date of audit: Date of last audit performed: Name of person performing self-audit: Signature: Name of person responsible for quality system: Signature: Number of non-compliances: Page
Quality Management System (QMS) for Active Pharmaceutical Ingredients (API) Manufacturers
Quality Management System (QMS) for Active Pharmaceutical Ingredients (API) Manufacturers integrating GMP (ICH Q7a) into ISO (9001: 2000) September 2005 Quality Management System - integrating GMP (ICH
Quality assurance of pharmaceuticals
QAPPR 12/16/06 12:10 PM Page i Quality assurance of pharmaceuticals A compendium of guidelines and related materials Volume 2, 2nd updated edition Good manufacturing practices and inspection QAPPR 12/16/06
Quality Management System MANUAL. SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702
Quality Management System MANUAL SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702 Doc. No. G5500 Rev. 9.1 Status : APPROVED Effective: 12/11/2014 Page 2 of 23 Quality Manual Table of Contents
